Aligos Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Aligos Therapeutics

05/05/2022 22:12

* Aligos Therapeutics Inc  ALGS.OQ  reported a quarterly
adjusted
loss of 84 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 73 cents per share.
    * Revenue rose 182.5% to $2.57 million from a year ago; 
analysts
expected zero. 
    * Aligos Therapeutics Inc's reported EPS for the quarter was
a
loss of 84 cents​.
    * The mean earnings estimate of analysts had risen by
about 5.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Aligos Therapeutics Inc shares had fallen by 42.3% this
quarter and lost 89.6% so far this year.
    * The company reported a quarterly loss of $35.62 million.
    * Wall Street's median 12-month price target for Aligos
Therapeutics Inc is $3.50 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 5 at 09:12 p.m.  ​All
figures in US dollars unless otherwise stated